PDF
(Download)
|
- Tea Tree (Melaleuca alternifolia, Myrtaceae)
- Acne
|
Date:
07-15-2016 | HC# 061651-548
|
Re: Tea Tree Oil Significantly Reduces Number of Acne Lesions
Malhi
HK, Tu J, Riley TV, Kumarasinghe SP, Hammer KA. Tea tree oil gel for mild to
moderate acne; a 12 week uncontrolled, open-label phase II pilot study. Australas J Dermatol. March 21, 2016;
[epub ahead of print]. doi: 10.1111/ajd.12465.
Acne
is a common skin condition caused by a combination of factors including excessive
sebum production, an immunological response to the bacteria Propionibacterium acnes, inflammation, and
abnormal desquamation of the follicular epithelium. Tea tree (Melaleuca alternifolia, Myrtaceae) leaf oil
has demonstrated antimicrobial and anti-inflammatory activity. Clinical studies
have evaluated the efficacy of tea tree oil in treating acne; however, they
have investigated preparations that contain concentrations of tea tree
essential oil (up to 5%) that are not available in commercial products. Hence,
the purpose of this uncontrolled, phase II pilot study was to evaluate the
efficacy and tolerability of a commercially available tea tree oil gel and
facial wash for the treatment of mild to moderate acne.
Men
and women (n = 18; 16-39 years old) with mild to moderate facial acne (defined
as 10-100 facial lesions) were recruited from January to September 2014 via
advertisements for this study conducted at 2 sites in Perth, Western Australia,
Australia. Included subjects also had ≤ 2 nodules and an investigator global
assessment (IGA) score of ≥ 2. Excluded subjects had a known allergy to tea
tree oil, had another current skin disease, were currently using steroids or
antibiotics, had severe underlying disease, were pregnant, were breastfeeding,
or participated in another clinical trial within the previous 12 weeks.
The
subjects received 200 mg/g Tea Tree Medicated Gel for Acne (Thursday
Plantation; Integria Healthcare; Brisbane, Queensland, Australia) and 7 mg/g Tea
Tree Face Wash for Acne (Thursday Plantation; Integria Healthcare). The
products contained tea tree oil meeting the specifications of the British Pharmacopoeia monograph for tea
tree oil, and both ISO 4730:2004 and Australian 2782-2009 standards for 'Oil of
Melaleuca, terpinen-4-ol type' (tea tree oil). The other ingredients of the
products were not reported. The subjects were instructed to use the products
twice daily on their face by first washing their face with 1 pump of the face
wash, patting it dry, and then applying a pea-sized amount of gel in a thin
layer to acne-affected areas. They were instructed to leave the product on for
at least 6 hours and wash it off only at the next application time.
The
primary endpoints of total lesion count and IGA score were recorded at 0, 4, 8,
and 12 weeks. The secondary endpoint of skin oiliness was recorded by the
investigator at 0, 4, 8, and 12 weeks. Study compliance was assessed via a
daily diary and by the investigator weighing the remaining product at each
visit. At the end of each week, subjects scored their acne on a 5-point scale ranging
from worse to significantly better. Tolerability was assessed via adverse
events and investigator score of erythema (redness), scaling, peeling,
induration (hardness), and dryness on a 5-point scale.
The
susceptibility of clinical isolates of P.
acnes to non-formulated tea tree oil, the gel, and the face wash were assessed
in triplicate using a standard broth microdilution method. The minimum
inhibitory concentrations (MICs) of each product were determined visually after
48 h of anaerobic incubation.
The
MIC of the unformulated oil (per volume) ranged from 0.25% to 1% (90% of the
isolates inhibited by 1%). The MIC of the gel ranged from 0.062-0.5% (per
volume) and the MIC of the face wash was < 0.25% (per volume).
Four
subjects were discontinued from the study; 2 for protocol violations and 2 by
request. Mean total lesion count significantly decreased at each visit compared
with baseline; there was a 25% decrease at 4 weeks (P < 0.05), 37% decrease
at 8 weeks (P < 0.01), and 54% decrease at 12 weeks (P < 0.001). IGA
score was significantly better at weeks 8 and 12 (P < 0.05 for both)
compared to baseline. Facial oiliness was significantly improved at week 12 (P
< 0.01) compared to baseline. Clinical efficacy (defined as ≥ 40% decrease
in lesion count at 12 weeks) was achieved for 79% (11/14) of subjects.
Based
on diary data, 11 subjects (79%) were compliant for all 12 weeks; data for the
remaining subjects were incomplete. The weekly opinion of the subjects most
frequently recorded (46%) was that their acne was about the same or slightly
improved (43%).
There
were no serious adverse events. One subject reported minor itching within the
first few days of applying the tea tree oil. At week 4, 1 subject experienced moderate
scaling, 1 had moderate peeling, and 1 had moderate dryness. Mean tolerability
scores for erythema (P < 0.05) and peeling (P < 0.01) were significantly decreased
at week 12 compared to baseline. Product acceptability was assessed for the gel
only; the lowest scores were for fragrance and ease of absorption and the
highest scores were for texture, consistency, and ease of application.
The
authors conclude that the use of a gel and face wash containing tea tree oil
for 12 weeks significantly reduced the number of acne lesions and was well
tolerated in subjects with mild to moderate acne. Both products showed
significant antibacterial activity against P.
acnes in vitro, suggesting that this may, in part, be the mechanism of
action. An acknowledged limitation of the study was the lack of a control; "it
remains possible that study factors such as the gel base product, or the regular,
structured facial care routine contributed to the improvement in acne." The
authors point out that a phase III, placebo-controlled, double-blind trial
would be required to evaluate this possibility.
The
product manufacturer, Thursday Plantation (Integria Healthcare), provided the study
materials. The study was supported by the Rural Industries Research and
Development Corporation (PRJ-006245).
—Heather S. Oliff,
PhD
|